Appointments

Glox Therapeutics, a precision medicine company spun out from the Universities of Oxford and Glasgow, has announced the appointments of Michael Murray (pictured) as chair of the board and Nel Moore as scientific advisory board member.

Murray serves as principal at Murray International Partners and holds almost three decades of experience in senior and interim management roles at several biotechnology/pharmaceutical companies, including Metallobio, Porton Biopharma, EnteroBiotix, Sosei Heptares and Amura Therapeutics, as well as an international commercial consultancy practice.

Alongside his current position, Murray teaches commercial intellectual property strategy on the Novo Nordisk Fellowship MBA in BioMedical Design programme, is a member of the Royal Society Industry College, an entrepreneur in residence at the University of Sheffield and a mentor at Cambridge Enterprise. He is also a registered technology transfer professional and a member of the International Technology Transfer Network.

Murray said: “I’m excited to help [Glox] grow and continue to progress its therapeutic programme to unlock the incredible potential of [its] technology.”

Moore also brings extensive experience to the company’s scientific advisory board. She previously held roles of increasing responsibility at AstraZeneca, culminating in her position as vice president of antibiotics development.

More recently, she has been supporting biotechnology companies with strategic planning, implementation and execution of business plans, as well as fundraising in her role as a senior research and development consultant at FWEast.